Recursion Secures FDA Alignment on Phase 3 Design for First-in-Class FAP Therapy
Recursion said the FDA agreed on a Phase 3 trial design for REC-4881 in FAP, a rare disease with no approved drugs.
Recursion said the FDA agreed on a Phase 3 trial design for REC-4881 in FAP, a rare disease with no approved drugs.
Recursion announces oversubscribed $200M raise, positive Phase 1b/2 FAP data for REC-4881, early REC-1245 activity, and Sanofi option milestone.
Nvidia's latest 13F filing reveals it sold positions in Applied Digital, WeRide, and Recursion Pharmaceuticals in Q4 2025, causing after-hours dips.
JPMorgan upgrades Recursion Pharmaceuticals to Overweight, raises price target to $11, and highlights blockbuster potential for REC-4881 and promising early cancer data.